Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZ32
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AZ32 is an orally bioavailable, small molecule inhibitor of the ataxia-telangiectasia mutated (ATM) kinase, originally developed by AstraZeneca. It is specifically designed to penetrate the blood-brain barrier (BBB), making it a candidate for treating central nervous system malignancies such as glioblastoma multiforme (GBM). By inhibiting ATM, a key sensor in the DNA damage response (DDR) pathway, AZ32 acts as a radiosensitizer, enhancing the lethal effects of ionizing radiation on tumor cells. Preclinical studies have demonstrated its efficacy in orthotopic mouse glioma models and its ability to reverse multidrug resistance in colorectal cancer by inhibiting the ABCG2 transporter. The compound is currently in the research phase and has not yet been approved for clinical use.
- Other names
- N-Methyl-4-(6-phenylimidazo[1,2-a]pyrazin-3-yl)benzamide
02
Targets
ABCG2 (Breast cancer resistance protein)ATM (Ataxia telangiectasia mutated protein)
Beyond the preview
Go deeper on AZ32.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZ32.